Clinical studies of ifosfamide/mesna at St Jude Children&apos;s Research Hospital, 1983-1988

Pratt, C.B.; Douglass, E.C.; Etcubanas, E.; Goren, M.P.; Green, A.A.; Hayes, F.A.; Horowitz, M.E.; Meyer, W.H.; Thompson, E.I.; Wilimas, J.A.; Pratt, C.B; Douglass, E.C; Etcubanas, E; Goren, M.P; Green, A.A; Hayes, F.A; Horowitz, M.E; Meyer, W.H; Thompson, E.I; Wilimas, J.A

Home

>

Node

>

Subnode

Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988

Pratt, C.B.; Douglass, E.C.; Etcubanas, E.; Goren, M.P.; Green, A.A.; Hayes, F.A.; Horowitz, M.E.; Meyer, W.H.; Thompson, E.I.; Wilimas, J.A.

Seminars in Oncology 16(1 Suppl. 3): 51-55

1989

ISSN/ISBN: 0093-7754

PMID: 2495567

Document Number: 340088

A phase-II study of ifosfamide with mesna, given intravenously daily for five days by bolus injection, has demonstrated the activity of ifosfamide against a spectrum of childhood malignant solid tumors. Ifosfamide presently is being investigated in alternative phase-I schedules, daily times three or every other day times three with the aim of delivering comparable amounts of ifosfamide without increasing toxicity--specifically, neurotoxicity. Additionally, response following ifosfamide treatment is being evaluated for previously untreated children with osteosarcoma and rhabdomyosarcoma after 6 weeks of treatment, and for previously untreated patients with Ewing's sarcoma after 9 weeks of treatment with ifosfamide/VP-16 (etoposide) given in combination.